Study Investigates GLP-1 Medications' Role in Preventing Lung Scarring Post-COVID
Researchers from the University of Hong Kong have explored the heightened risk of respiratory complications in individuals with type 2 diabetes following COVID-19, particularly focusing on the potential protective effects of GLP-1 medications. Their findings, published in the Journal of Virology, reveal that inflammatory immune cells may play a significant role in lung scarring post-infection, and that GLP-1 receptor agonists could mitigate this risk.
According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 8 individuals in the U.S. is affected by diabetes, with type 2 diabetes accounting for over 90% of these cases. GLP-1 receptor agonists, such as semaglutide and tirzepatide, are commonly prescribed to manage type 2 diabetes and obesity, and they have been shown to improve blood sugar levels and promote weight loss. Additionally, these medications may lower the risk of cardiovascular and kidney diseases.
Individuals with type 2 diabetes face an increased likelihood of developing long COVID and pulmonary fibrosis, a condition characterized by the accumulation of scar tissue in the lungs that complicates breathing. To investigate this further, the researchers conducted a series of experiments combining human sample analyses with mouse models. They began by analyzing data from a prior long COVID study involving 90 hospitalized patients, including 11 with type 2 diabetes. This analysis focused on immune cell activity during hospitalization and again 2 to 3 months post-infection, revealing significant differences in genes associated with inflammation and lung scarring.
Subsequently, diabetic and non-diabetic mice were infected with SARS-CoV-2 to assess the long-term lung damage associated with diabetes. In another experiment, the researchers depleted macrophages—immune cells that contribute to inflammation—to determine their role in lung scarring post-infection. Finally, they treated infected diabetic mice with a GLP-1 receptor agonist and compared their outcomes to untreated counterparts.
The results consistently indicated a link between type 2 diabetes and lung scarring related to long COVID. In the human study, individuals with type 2 diabetes exhibited increased activity in monocytes—immune cells that can develop into macrophages—up to three months after COVID-19. They also showed elevated levels of inflammatory genes and proteins compared to non-diabetic individuals.
In the mouse experiments, diabetic mice experienced more severe infections, greater weight loss, and higher viral loads, alongside increased activity of a fibrosis-related gene absent in non-diabetic mice. Moreover, the presence of macrophages in the lungs of diabetic mice post-infection was significantly higher than in their non-diabetic counterparts. When these immune cells were removed, the resulting mice exhibited less lung inflammation and scarring, highlighting the macrophages' role in lung damage.
The final experiment demonstrated that GLP-1 medications significantly reduced lung scarring in treated diabetic mice compared to untreated ones. These drugs appeared to alter macrophage responses to infection, indicating a potential therapeutic pathway.
Lead study author Runhong Zhou, PhD, emphasized that the findings suggest pro-inflammatory macrophage infiltration as a major contributor to long COVID-related pulmonary fibrosis. Zhou stated, 'We think that COVID-19 infection-induced proinflammatory macrophage infiltration is a major driver of long COVID-related pulmonary fibrosis.' He also noted that while the findings are promising, they are preliminary and based on a limited number of mice, necessitating further validation in larger studies and eventually in human trials.
Experts in the field, such as Gillian Goddard, MD, and Fady Youssef, MD, acknowledge the study's exciting implications but caution that more research is needed before GLP-1 medications can be recommended for treating long COVID. Goddard pointed out that individuals with type 2 diabetes already have elevated baseline inflammation, which may exacerbate the severity of COVID-19 symptoms. Youssef highlighted that the study's intriguing findings suggest GLP-1 drugs might reduce lung scarring independently of blood sugar improvements, indicating a direct impact on the immune cells involved in lung damage.
This study opens new avenues for understanding the relationship between diabetes, COVID-19, and potential therapeutic interventions, although further research is essential to confirm these findings and their clinical applicability.




